Proposition - PharmXpert Academy

The Korean Pharmaceutical Company List 453
41. Kyongbo Pharm. Co., Ltd.
1. Company Information
Company Kyongbo Pharm. Co., Ltd.
Representative Kim, Young Eun E-mail
Representative
Representative
Phone No.
+82-41-545-0456
Fax No.
+82-41-546-8427
Hompage www.kbpharma.co.kr
Address 345-6 Silok-Dong, Asan-Si, Chungcheong Nam-Do, 336-320, Korea
Research
Institute Address
345-6 Silok-Dong, Asan-Si, Chungcheong Nam-Do, 336-320, Korea
Year of
1987 Sales (‘06) 55 Million$
Establishment
The Number of
Total
The Number of
Total
Employees (06‘) 186 Researchers (‘06) 12
Contact Person Na, Jong yul Contact Phone +82-41-545-0456
Contact E-mail jyna@kbpharma.co.kr Contact Fax +82-41-545-0456
Introduction of Company
Kyongbo Pharmaceutical Co., Ltd. started as Kyongbo Chemical, a specialist in manufacturing
raw material medicine that leads the area of raw material medicine in 1987 based on its
future-oriented mission of contributing to the health and the life of human beings with precision
chemistry, one of the promising advanced industries in the 21st century.
Kyongbo Chemical has shortened and advanced the manufacturing process through innovation
of manufacturing technology with the objective of developing new substances. Kyongbo Chemical
has the management strategy of obtaining competitive edge by producing the raw materials with
high yield most inexpensively in terms of economic efficiency.
The company that was created as raw material medicine part of Chong Kun Dang
Pharmaceutical Corp. was separated in Jan. 1996. With experiences in Chong Kun Dang, trained
personnel and capital power, production technology of the most products in Korea and product
approval of FDA for the first time in Korea, Kyongbo has successfully developed Cefaclor,
antibiotic widely used in the world, for the first time in Asia as a small and medium-sized
company.
Kyongbo Chemical has obtained Quality Management System (ISO 9001) and Environment
Management System (ISO 14001) for the first time in Korea in the area of pharmacy, as well as
BGMP, the quality license system in the area of raw material medicine, taking the lead in
pharmaceutical industry. Kyongbo has prepared DMF for advancing into the European market, IDL
for advancing into the Chinese market, FDA and c-GMP for advancing into the American market.
Kyongbo Pharmaceutical Co., Ltd. possesses high-level production technology of about 60
kinds such as Penicillin antibiotics and cephalosporin antibiotics, hyperlipidemia medicine and
Proton Pump medicine for digestive ulcer. In particular, cephalosporin antibiotics use 7-ACA
(basic ingredient) produced with fermentation technology of Chong Kun Dang Pharmaceutical
Corp. It manufactures raw material medicine using the best combined technology of Kyongbo
Pharmaceuical Co., Ltd. and Bardia Farma of Italy. Kyongbo Pharmaceutical Co., Ltd. is the only
one company connected to finished medicine of Chong Kun Dang and has obtained the highest
sales efficiency with excellent marketing capacity at home and abroad.
New challenge for finished medicine is to find the better raw materials for the contribution of
the public health.
As a result, it produces and sells about 30 types of special medicine as well as 15 types of
general medicine.
Kyongbo Chemical is always at its best to make the better quality medicine to provide more
comfortable life.